
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Obes Facts</journal-id><journal-id journal-id-type="iso-abbrev">Obes Facts</journal-id><journal-id journal-id-type="publisher-id">OFA</journal-id><journal-title-group><journal-title>Obesity Facts</journal-title></journal-title-group><issn pub-type="ppub">1662-4025</issn><issn pub-type="epub">1662-4033</issn><publisher><publisher-name>S. Karger GmbH</publisher-name><publisher-loc>Wilhelmstrasse 20A, P.O. Box &#x000b7; Postfach &#x000b7; Case postale, D&#x02013;79095, Freiburg, Germany &#x000b7; Deutschland &#x000b7; Allemagne, Phone: +49 761 45 20 70, Fax: +49 761 4 52 07 14, information@karger.de</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23434893</article-id><article-id pub-id-type="pmc">5644737</article-id><article-id pub-id-type="doi">10.1159/000348573</article-id><article-id pub-id-type="publisher-id">ofa-0006-0009</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Fat-Free Mass and Fasting Glucose Values in Patients with and without Statin Therapy Assigned to Age Groups between &#x0003c;60 and &#x0003e;75 Years</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dzien</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Winner</surname><given-names>Hannes</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Theurl</surname><given-names>Engelbert</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dzien-Bischinger</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lechleitner</surname><given-names>Monika</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="aff1"><sup>a</sup>Medical Center Hentschelhof, Innsbruck, University of Salzburg, Salzburg, Austria</aff><aff id="aff2"><sup>b</sup>Department of Economics and Social Sciences, University of Salzburg, Salzburg, Austria</aff><aff id="aff3"><sup>c</sup>Department of Public Economics, University of Innsbruck, Innsbruck, Zirl, Austria</aff><aff id="aff4"><sup>d</sup>Department of Internal Medicine, Hospital Hochzirl, Zirl, Austria</aff><author-notes><corresp id="cor1">*Prim. ao.Univ.-Prof. Dr. Monika Lechleitner, Department of Internal Medicine, Hospital Hochzirl, 6170 Zirl (Austria), <email>monika.lechleitner@tilak.at</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>21</day><month>2</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>2</month><year>2013</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>6</volume><issue>1</issue><fpage>9</fpage><lpage>16</lpage><history><date date-type="received"><day>31</day><month>1</month><year>2012</year></date><date date-type="accepted"><day>25</day><month>7</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 by S. Karger GmbH, Freiburg</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable tothe online version of the article only. Distribution permitted for non-commercial purposes only.</license-p></license></permissions><abstract><sec><title>Objective</title><p>The aging-associated changes in body composition result in an increased cardiometabolic risk. A tremendous reduction of cardiovascular morbidity and mortality can be obtained by statin therapy. Statins are well tolerated, with myopathy as the most serious negative side effect. Some recently published studies indicate that the incidence of type 2 diabetes might be increased during intensified statin therapy. The aim of our study was to investigate whether statin therapy has an influence on the aging-associated changes in fat-free mass (FFM).</p></sec><sec><title>Methods</title><p>A total of 3,280 persons attending a medical outdoor center between January 2005 and July 2011 were assigned to 3 age groups from &#x0210b;60 to &#x0003e;75 years. Clinical data, body mass index (BMI), and body composition were evaluated in the different age groups in patients with and without statin therapy. To analyze the impact of statin use on FFM, we regressed a patient's FFM on an interaction term between statin use and age and other control variables.</p></sec><sec><title>Results</title><p>Aging was associated with a decrease in BMI and FFM, while fat mass continuously increased up to the age of &#x0003e;75 years. This was paralleled by a continuous increase in fasting glucose levels in patients with and without statin therapy. The loss of FFM between the age group &#x0210b;60 years and &#x0003e;75 years was more pronounced in statin-treated patients (10.88%) than in non-statin users (8.47%). Creatine phosphokinase values revealed a decrease of 7.77 U/l between the age groups &#x0210b;60 and &#x0003e;75 years in non-statin users and of 14.75 U/l in statin users. Statistical analysis indicated that the effect of statin therapy on FFM is more pronounced in younger than in older patients.</p></sec><sec><title>Conclusions</title><p>Patients under statin therapy seem to be more vulnerable to the aging-associated lowering of FFM. Diagnostic procedures and interventions to prevent a loss of muscle mass might be of particular advantage in elderly patients under statin therapy.</p></sec></abstract><kwd-group><title>Key Words</title><kwd>Fat-free mass</kwd><kwd>Aging</kwd><kwd>Statin</kwd></kwd-group><counts><table-count count="2"/><ref-count count="48"/><page-count count="8"/></counts></article-meta></front><body><sec id="sec1_1"><title>Background</title><p>Aging is related to a decrease in muscle mass and an increase in fat mass, which corresponds with an increased risk for metabolic disorders, type 2 diabetes, and cardiovascular complications [<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>]. The relative loss of fat-free mass (FFM), an increase in fat mass, and abdominal fat distribution are further associated with physical impairments and a higher mortality rate [<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>]. Increased abdominal adipose tissue causes unfavorable changes in insulin sensitivity and plasma lipid values [<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>]. Subclinical inflammation of adipose tissue surrounding and infiltrating muscles is supposed to be one mechanism responsible for the muscular abnormalities in the aging process [<xref rid="B10" ref-type="bibr">10</xref>]. In obese patients, exaggerated loss of muscle mass can result in sarcopenic obesity [<xref rid="B11" ref-type="bibr">11</xref>,] with a further increase in the cardiovascular risk [<xref rid="B12" ref-type="bibr">12</xref>].</p><p>One of the most important and effective developments in the pharmacological interventions to reduce cardiovascular complications was the introduction of statin therapy. Landmark studies and meta-analyses clearly demonstrated that statin therapy results in a significant reduction of cardiovascular morbidity and mortality [<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>]. This is also supported by recently published data from the Cholesterol Treatment Trialists&#x02019; meta-analysis including data from &#x0003e;170,000 participants from 26 randomized statin trials [<xref rid="B15" ref-type="bibr">15</xref>]. In general, statins are well tolerated and safe, with myopathy as the most serious negative side effect [<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref>]. Muscular damage during statin therapy ranges from muscle weakness, aches, and fatigue to rhabdomyolysis with the potential risk of renal failure. The occurrence of general myopathies has been estimated to range from 1 to 10%, while rhabdomyolysis was reported to occur in 0.1% of all statin users [<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B17" ref-type="bibr">17</xref>]. The creatine phosphokinase (CPK) plasma levels serve as an indicator for muscle cell damage and death [<xref rid="B14" ref-type="bibr">14</xref>], but are also related to muscle mass [<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>]. The risk of myopathy under statin therapy increases with an increasing dosage of the statin, in the case of multiple medication, and especially in elderly individuals [<xref rid="B17" ref-type="bibr">17</xref>].</p><p>Recently published retrospective analyses of statin studies indicate that statin therapy &#x02013; despite the tremendous preventive effects on cardiovascular disease &#x02013; might cause an increased risk of type 2 diabetes [<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>,<xref rid="B22" ref-type="bibr">22</xref>]. Evidence for a dose-dependent association between statin and diabetes risk was described in a meta-analysis [<xref rid="B22" ref-type="bibr">22</xref>], but the underlying mechanisms remain a matter of speculation. It could be hypothesized that distinct effects of statin therapy on muscle cells result in muscle insulin resistance [<xref rid="B23" ref-type="bibr">23</xref>]. Statin therapy could also affect the age-associated decrease in muscle strength and muscle mass [<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B24" ref-type="bibr">24</xref>,<xref rid="B25" ref-type="bibr">25</xref>]. Myopathy under statin therapy is multifactorial. A modulation of the respiratory chain of mitochondria [<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>], an increase in muscle cell apoptosis [<xref rid="B16" ref-type="bibr">16</xref>], and an upregulation in the expression of genes that modulate membrane repair were described as a part of the complex underlying mechanism of statin myopathy [<xref rid="B28" ref-type="bibr">28</xref>].</p><p>Regarding the debate about a possibly increased incidence of type 2 diabetes under statin therapy and the side effects of statins on muscle cells, it seemed of interest to us to study whether statin therapy is related to an exaggerated aging-associated decrease in FFM. For this purpose, a cohort of patients with and without statin therapy was assigned to different age groups. To analyze the effect of statin use on the FFM, we regress a patient's FFM on the statin use and on other control variables.</p></sec><sec sec-type="subjects|methods" id="sec1_2"><title>Patients and Methods</title><p>Between January 2005 and July 2011, a total of 3,280 persons attended a medical outdoor center for diagnostic and/or therapeutic interventions. All patients underwent clinical routine controls and laboratory measurements. The level of physical exercise was determined by the reported frequency of sporting activities per week.</p><p>Laboratory tests were performed from blood samples taken in the morning after an overnight fasting period. Patients were asked to restrain from vigorous physical exercise 48 h before the laboratory and clinical measurements were performed. Total CPK activity was determined by &#x02018;Menarini autoanalyzer reagent FGENT CK-NAC MONO&#x02019;, and normal CPK activity ranged from 24 to 170 U/l.</p><p>Body composition (lean mass, fat mass, proportion of fat mass) of the patients was estimated using bioelectrical impedance analysis with body composition monitor HBF-306-E &#x02018;OMRON&#x02019; bipolar devices [<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>]. Information on BMI and on FFM was collected from all patients [<xref rid="B29" ref-type="bibr">29</xref>,<xref rid="B30" ref-type="bibr">30</xref>].</p><p>Patients were assigned to 3 age groups from &#x0210b;60 to &#x0003e;75 years of age, thereby also separating patients with and without statin therapy. The patients were defined as statin users when a continuous intake of statins was reported for at least 4 weeks (duration of medication 1&#x02013;78 months). A sub-analysis was performed for patients under statin therapy with CPK values in the normal range compared to those with CPK values above 170 U/L. None of the patients revealed renal impairments. A further assignment of the patients into 3 groups was performed according to the body mass index (BMI) &#x02013; with normal BMI (&#x0210b;25 kg/m<sup>2</sup>), overweight (25&#x02013;30 kg/m<sup>2</sup>), and obesity (&#x0003e;30 kg/m<sup>2</sup>).</p><p>Patients with acute vascular complications (myocardial infarction, coronary interventions, stroke, cerebral ischemia within 12 weeks), acute or chronic inflammatory disease, severe renal or hepatic failure or chemotherapy, or non-statin lipid-lowering drug therapy were excluded from our evaluation.</p><p>No changes in lifestyle during the last 3 months were stated by the patients, and none of the patients reported about a current weight reduction program. Beside the clinical status, an increased erythrocyte sedimentation rate, C-reactive protein and leukocyte count were the diagnostic criteria for inflammatory disease. Renal disease was defined by a serum creatinine &#x0003e;1.5 mg/dl and impaired liver function by a double or higher increase of hepatic enzyme levels.</p><p>The share of people engaging in regular sports activities was about 43%, while approximately 24% patients in our sample were smokers and 11% were patients with diagnosed type 2 diabetes mellitus.</p><p>Informed consent about the participation in the study was requested from all of the patients.</p><sec id="sec2_1"><title>Statistical Analysis</title><p>First of all, we applied a descriptive analysis by which we compared FFM of statin users and non-statin users across different age cohorts. Furthermore, in order to analyze the impact of statin use on FFM more systematically, we regressed a patient's FFM on an indicator variable informing about statin use, an interaction term between statin use and age, and other control variables. The latter include a patient's age (in years), gender (dummy variable, entry 1 indicating male patients), and two indicator variables informing about nicotine consumption (entry 0 for non-smokers and entry 1 for smokers) and sporting activities (entry 1 for patients engaging in sporting activities at least once a week, and entry 0 for all other patients). In all regressions, we used standard ordinary least-squares methods and excluded outlying observations at the upper and lower percentile of the remainder error (2% of the sample, or about 60 observations). We applied our regressions to two samples, one including all patients and one including only patients with CPK levels below 170 U/l.</p></sec></sec><sec sec-type="results" id="sec1_3"><title>Results</title><p>In the whole study cohort of 3,280 patients a total of 600 patients were on continuous statin therapy, and 2,680 were non-users of statins. The highest frequency of statin prescription was in the age group 60&#x02013;75 years. 131 (21.8%) of the patients on continuous statin therapy revealed increased CPK values. None of them developed an impaired renal function.</p><p>BMI revealed a decrease, with the lowest values in the oldest age group, i.e. &#x0003e;75 years, in patients with and without statin therapy (table <xref ref-type="table" rid="T1">1</xref>). FFM decreased continuously with increasing age. The loss of FFM between the age group &#x0210b;60 years and &#x0003e;75 years was more pronounced in statin-treated patients (10.88%) than in non-statin users (8.47%). This was paralleled by a decrease in CKP-values, with a difference of 7.77 U/l between the age groups &#x0210b;60 and &#x0003e;75 years in non-statin users and of 14.75 U/l in statin users.</p><p>In statin users and in non-statin users the percentage of fat mass increased continuously with aging, with the highest values in the age group &#x0003e;75 years. In all age groups the BMI and corresponding FFM values were higher in statin users than in non-statin users (table <xref ref-type="table" rid="T1">1</xref>), whereas a higher percentage of fat mass was only observed in the younger study group &#x0210b;60 years of age. Fasting glucose levels revealed a continuous increase with increasing age in non-statin users and in statin users.</p><p>With respect to the data evaluation according to subgroups defined by the BMI values, non-statin users in the overweight and obese groups (25&#x02013;30 kg/m<sup>2</sup> and &#x0003e;30 kg/m<sup>2</sup>) were older than in the normal-weight group (&#x0210b;25 kg/m<sup>2</sup>) (table <xref ref-type="table" rid="T1">1</xref>). Overall, statin users were older than non-statin users. The percentage of body fat mass in the BMI group &#x0210b;25 kg/m<sup>2</sup> was higher in statin users than in non-statin users, while no such pronounced difference was found for overweight or obese patients. In all BMI groups statin users &#x02013; except those with increased CPK values &#x02013; showed lower values for FFM than non-statin users. Fasting glucose and triglyceride values revealed a continuous increase with increasing BMI in statin users and in non-statin users. In the BMI subgroups fasting glucose and triglyceride levels were higher in statin users compared to non-statin users (table <xref ref-type="table" rid="T1">1</xref>).</p><p>A more systematic picture of the relationship between FFM and statin use is provided in our regression results in table <xref ref-type="table" rid="T2">2</xref>. First of all, it can be seen that male patients obtained a higher FFM than female patients. Furthermore, age was associated with a lower FFM. Nicotine consumption and sporting activities played an insignificant role. Additionally, we found a (highly) significant parameter estimate for statin use, indicating that patients undergoing a corresponding therapy revealed a higher FFM. We also observed that this effect of statin therapy declined over age, which is indicated by the significantly negative coefficient on the interaction term between statin use and the age variable. This, in turn, suggests that the effect of statin therapy on FFM is more pronounced in younger patients than in older ones. Both findings, i.e. the positive coefficient on the statin variable and the negative one on the interaction term between statin use and age, are in accordance with the descriptive evidence from table <xref ref-type="table" rid="T1">1</xref>. In conclusion, we cannot see any systematic differences regarding the effects of statin therapy on FFM (and also its change over years) between our sample of all patients and the one focusing on 2,613 patients, with CPK equal to or lower than 170 U/l (columns 1 and 2 in table <xref ref-type="table" rid="T2">2</xref>).</p></sec><sec sec-type="discussion" id="sec1_4"><title>Discussion</title><p>The results of our evaluation indicate that patients under statin therapy reveal a more pronounced aging-associated decrease in FFM between the age groups of &#x0210b;60 and &#x0003e;75 years than in patients without statin therapy. This loss of FFM could be due to the complex morbidity of statin-treated patients but also due to a possible direct influence on FFM. Multivariate analysis revealed a strong positive relationship of FFM to male sex and to statin use. The association of FFM with male sex is well known and explained by the anabolic hormone effects [<xref rid="B31" ref-type="bibr">31</xref>,<xref rid="B32" ref-type="bibr">32</xref>].</p><p>BMI and FFM values were higher in all of the patients treated with statin than in those without statin therapy. This observation could partially be due to a higher level of physical exercise [<xref rid="B33" ref-type="bibr">33</xref>]. Recently published studies reported an increased lean mass following resistance training under statin therapy and a more favorable outcome during rehabilitation procedures in elderly patients [<xref rid="B34" ref-type="bibr">34</xref>,<xref rid="B35" ref-type="bibr">35</xref>]. As body weight and BMI are indicators of FFM [<xref rid="B36" ref-type="bibr">36</xref>,] the higher FFM in our statin patients might simply be explained by the higher BMI values.</p><p>CPK activity is known to be related to FFM [<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>]. Low CPK levels are related to muscle weakness [<xref rid="B37" ref-type="bibr">37</xref>], sarcopenia, and frailty [<xref rid="B38" ref-type="bibr">38</xref>]. In all of our patients, the lowest values for CPK, BMI and FFM were found in the oldest age group, in statin-treated patients, and in those without statin therapy. This finding is in accordance with previously published epidemiological data and clinical studies concerning a decrease of BMI at an advanced age [<xref rid="B39" ref-type="bibr">39</xref>,<xref rid="B40" ref-type="bibr">40</xref>], resulting in an increased risk for physical impairment and frailty [<xref rid="B2" ref-type="bibr">2</xref>].</p><p>Fat mass increases with increasing age [<xref rid="B5" ref-type="bibr">5</xref>,<xref rid="B6" ref-type="bibr">6</xref>] and is related to a higher cardiometabolic risk, but also to a higher rate of muscle loss and sarcopenia [<xref rid="B12" ref-type="bibr">12</xref>]. Greater total and abdominal adipose tissue mass is associated with subclinical inflammation [<xref rid="B41" ref-type="bibr">41</xref>], a process possibly enhancing sarcopenia [<xref rid="B42" ref-type="bibr">42</xref>]. Because statins also show anti-inflammatory effects, it could be speculated that statins improve sarcopenia [<xref rid="B43" ref-type="bibr">43</xref>]. Recently, an improved outcome during inpatient rehabilitation was described during statin therapy in older people; however, no measurements on FFM were provided [<xref rid="B35" ref-type="bibr">35</xref>].</p><p>Fasting glucose values of all our patients revealed an increase with increasing age, and peak fasting glucose levels were found in patients &#x0003e;75 years with and without statin therapy. This aging-associated increase in fasting glucose levels was also described by several other studies [<xref rid="B44" ref-type="bibr">44</xref>,<xref rid="B45" ref-type="bibr">45</xref>] and is primarily explained by the aging-associated increase in insulin resistance. In accordance with this, we could observe an increase in fat mass with increasing age, with a higher risk for insulin resistance [<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>].</p><p>In patients without statin therapy, total cholesterol increased up to the age group of 60&#x02013;74 years and decreased thereafter. This could be explained by aging-associated impairments of lipoprotein metabolism resulting in an increase in total cholesterol [<xref rid="B46" ref-type="bibr">46</xref>,<xref rid="B47" ref-type="bibr">47</xref>]. Total cholesterol was the lowest in the age group &#x0003e;75 years, which was paralleled by a decrease of serum triglycerides in patients with statin therapy. This might be related to reduced food intake, with a high risk for malnutrition at an advanced age [<xref rid="B2" ref-type="bibr">2</xref>].</p><p>Limitations of our evaluation are the fact that all study participants were patients admitted to an outdoor center and not a cohort of healthy individuals. However, all of our study participants were community-dwelling subjects without significant functional impairments.</p><p>Our findings indicate that patients under statin therapy reveal a more pronounced decrease in FFM than patients without statin therapy. It remains speculative whether this relationship is causal as a consequence of statin myopathy or due to the higher morbidity in patients needing statin therapy. Considering statin long-term safety [<xref rid="B48" ref-type="bibr">48</xref>,] further studies will be required especially for patients at an advanced age.</p></sec><sec sec-type="conclusions" id="sec1_5"><title>Conclusions</title><p>Patients under statin therapy revealed a more pronounced aging-associated decline in FFM than patients without statin therapy. Aging was related to an increase in fat mass in statin users and non-users, which was paralleled by an increase in fasting glucose values. Interventions to prevent a more pronounced decline in muscle mass could be of particular advantage for elderly patients under statin therapy.</p></sec><sec id="sec1_6"><title>Disclosure Statement</title><p>The authors declare no conflict of interest. No sponsorship was obtained for the study.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koopman</surname><given-names>R</given-names></name><name><surname>van Loon</surname><given-names>LJC</given-names></name></person-group><article-title>Aging, exercise, and muscle protein metabolism</article-title><source>J Appl Physiol</source><year>2009</year><volume>106</volume><fpage>2040</fpage><lpage>2048</lpage><pub-id pub-id-type="pmid">19131471</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fielding</surname><given-names>RA</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><name><surname>Evans</surname><given-names>WJ</given-names></name><name><surname>Bhasin</surname><given-names>S</given-names></name><name><surname>Morley</surname><given-names>JE</given-names></name><name><surname>Newman</surname><given-names>AB</given-names></name><name><surname>Abellan van Kan</surname><given-names>G</given-names></name><name><surname>Andrieu</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Breuille</surname><given-names>D</given-names></name><name><surname>Cederholm</surname><given-names>T</given-names></name><name><surname>Cahndler</surname><given-names>J</given-names></name><name><surname>De Meynard</surname><given-names>C</given-names></name><name><surname>Donin</surname><given-names>L</given-names></name><name><surname>Harris</surname><given-names>T</given-names></name><name><surname>Kannt</surname><given-names>A</given-names></name><name><surname>Keime Guibert</surname><given-names>F</given-names></name><name><surname>Onder</surname><given-names>G</given-names></name><name><surname>Pappanicolaou</surname><given-names>D</given-names></name><name><surname>Rolland</surname><given-names>Y</given-names></name><name><surname>Rooks</surname><given-names>D</given-names></name><name><surname>Sieber</surname><given-names>C</given-names></name><name><surname>Souhami</surname><given-names>E</given-names></name><name><surname>Verlaan</surname><given-names>D</given-names></name><name><surname>Zamboni</surname><given-names>M</given-names></name></person-group><article-title>Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia</article-title><source>J Am Med Dir Assoc</source><year>2011</year><volume>12</volume><fpage>249</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">21527165</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wroblewski</surname><given-names>AP</given-names></name><name><surname>Amati</surname><given-names>F</given-names></name><name><surname>Smiley</surname><given-names>MA</given-names></name><name><surname>Goodpaster</surname><given-names>B</given-names></name><name><surname>Wright</surname><given-names>V</given-names></name></person-group><article-title>Chronic exercise preserves lean muscle mass in master athletes</article-title><source>Phys Sportmed</source><year>2011</year><volume>39</volume><fpage>172</fpage><lpage>178</lpage></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lechleitner</surname><given-names>M</given-names></name></person-group><article-title>Obesity and the metabolic-syndrome in the elderly &#x02013; a mini-review</article-title><source>Gerontology</source><year>2009</year><volume>54</volume><fpage>253</fpage><lpage>259</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wannamethee</surname><given-names>SG</given-names></name><name><surname>Shaper</surname><given-names>AG</given-names></name><name><surname>Lennon</surname><given-names>L</given-names></name><etal/></person-group><article-title>Decreased muscle mass and increased central adiposity are independently related to mortality in older men</article-title><source>Am J Clin Nutr</source><year>2007</year><volume>86</volume><fpage>1334</fpage><lpage>134</lpage></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>TS</given-names></name><name><surname>Tajar</surname><given-names>A</given-names></name><name><surname>Lean</surname><given-names>MEJ</given-names></name></person-group><article-title>Obesity and weight management in the elderly</article-title><source>Br Med Bull</source><year>2011</year><volume>97</volume><fpage>169</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">21325341</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamboni</surname><given-names>M</given-names></name><name><surname>Mazzali</surname><given-names>G</given-names></name><name><surname>Zoico</surname><given-names>E</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Di Francesco</surname><given-names>V</given-names></name><name><surname>Fantin</surname><given-names>F</given-names></name><name><surname>Bissoli</surname><given-names>L</given-names></name><name><surname>Bosello</surname><given-names>O</given-names></name></person-group><article-title>Health consequences of obesity in the elderly: a review of four unresolved questions</article-title><source>Int J Obes</source><year>2005</year><volume>29</volume><fpage>1011</fpage><lpage>1029</lpage></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>GR</given-names></name><name><surname>Chandler-Laney</surname><given-names>PC</given-names></name><name><surname>Brock</surname><given-names>PW</given-names></name><name><surname>Lara-Castro</surname><given-names>C</given-names></name><name><surname>Fernandez</surname><given-names>JR</given-names></name><name><surname>Gower</surname><given-names>BA</given-names></name></person-group><article-title>Fat distribution, aerobic fitness, blood lipids, and insulin sensitivity in African-American and European-American women</article-title><source>Obesity</source><year>2010</year><volume>18</volume><fpage>274</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">19661963</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeNino</surname><given-names>WF</given-names></name><name><surname>Tschernof</surname><given-names>A</given-names></name><name><surname>Dionne</surname><given-names>IJ</given-names></name><name><surname>Toth</surname><given-names>MJ</given-names></name><name><surname>Ades</surname><given-names>PA</given-names></name><name><surname>Sites</surname><given-names>CK</given-names></name><name><surname>Poehlman</surname><given-names>ET</given-names></name></person-group><article-title>Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women</article-title><source>Diabetes Care</source><year>2001</year><volume>24</volume><fpage>925</fpage><lpage>932</lpage><pub-id pub-id-type="pmid">11347756</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoico</surname><given-names>E</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Di Francesco</surname><given-names>V</given-names></name><name><surname>Sepe</surname><given-names>A</given-names></name><name><surname>Olioso</surname><given-names>D</given-names></name><name><surname>Pizzini</surname><given-names>F</given-names></name><name><surname>Fantin</surname><given-names>F</given-names></name><name><surname>Bosello</surname><given-names>O</given-names></name><name><surname>Cominacini</surname><given-names>L</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name><name><surname>Zamboni</surname><given-names>M</given-names></name></person-group><article-title>Adipose tissue infiltration in skeletal muscle of healthy elderly men: relationship with body composition, insulin resistance, and inflammation at the systemic and tissue level</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2010</year><volume>65</volume><fpage>295</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">19864639</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>DL</given-names></name><name><surname>Baumgartner</surname><given-names>RN</given-names></name></person-group><article-title>Sarcopenic obesity</article-title><source>Clin Geriatr Med</source><year>2011</year><volume>27</volume><fpage>401</fpage><lpage>421</lpage><pub-id pub-id-type="pmid">21824555</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephen</surname><given-names>WC</given-names></name><name><surname>Janssen</surname><given-names>I</given-names></name></person-group><article-title>Sarcopenic-obesity and cardiovascular risk in the elderly</article-title><source>J Nutr Health Aging</source><year>2009</year><volume>13</volume><fpage>460</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">19390754</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>EJ</given-names></name><name><surname>Rachlis</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Devereaux</surname><given-names>PJ</given-names></name><name><surname>Arora</surname><given-names>P</given-names></name><name><surname>Perri</surname><given-names>D</given-names></name></person-group><article-title>Primary prevention of cardiovascular mortality and events with statin treatments. A network meta-analysis involving more than 65,000 patients</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>52</volume><fpage>1769</fpage><lpage>1781</lpage><pub-id pub-id-type="pmid">19022156</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The Task Force for the management of dyslipidemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)</collab></person-group><article-title>ESC/EAS guidelines for the management of dyslipidaemias</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><fpage>1769</fpage><lpage>1818</lpage><pub-id pub-id-type="pmid">21712404</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cholesterol Treatment Trialists' (CTT) Collaboration</collab></person-group><article-title>Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized control trials</article-title><source>Lancet</source><year>2011</year><volume>376</volume><fpage>1670</fpage><lpage>1681</lpage></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dirks</surname><given-names>AJ</given-names></name><name><surname>Jones</surname><given-names>KM</given-names></name></person-group><article-title>Statin-induced apoptosis and skeletal myopathy</article-title><source>Am J Physiol Cell Physiol</source><year>2006</year><volume>291</volume><fpage>C1208</fpage><lpage>C1212</lpage><pub-id pub-id-type="pmid">16885396</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meador</surname><given-names>BM</given-names></name><name><surname>Huey</surname><given-names>KA</given-names></name></person-group><article-title>Statin-associated myopathy and its exacerbation with exercise</article-title><source>Muscle Nerve</source><year>2010</year><volume>42</volume><fpage>469</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">20878737</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swaminathan</surname><given-names>R</given-names></name><name><surname>Ho</surname><given-names>CS</given-names></name><name><surname>Donnan</surname><given-names>SP</given-names></name></person-group><article-title>Body composition and plasma creatine kinase activity</article-title><source>Am J Clin Biochem</source><year>1988</year><volume>25</volume><fpage>389</fpage><lpage>391</lpage></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mairiaux</surname><given-names>P</given-names></name><name><surname>Buchet</surname><given-names>JP</given-names></name><name><surname>Bettonville</surname><given-names>MN</given-names></name></person-group><article-title>Serum creatine kinase: relationship to lean body mass in a &#x02018;real-life&#x02019; situation</article-title><source>Clin Chem</source><year>1984</year><volume>30</volume><fpage>1428</fpage><lpage>1429</lpage><pub-id pub-id-type="pmid">6744617</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sattar</surname><given-names>N</given-names></name><name><surname>Preiss</surname><given-names>D</given-names></name><name><surname>Murray</surname><given-names>HM</given-names></name><name><surname>Welsh</surname><given-names>P</given-names></name><name><surname>Buckley</surname><given-names>BM</given-names></name><name><surname>de Craen</surname><given-names>AJ</given-names></name><name><surname>Seshasai</surname><given-names>SR</given-names></name><name><surname>McMurreay</surname><given-names>JJ</given-names></name><name><surname>Freeman</surname><given-names>DJ</given-names></name><name><surname>Jukema</surname><given-names>JW</given-names></name><name><surname>Macfarlane</surname><given-names>PW</given-names></name><name><surname>Packard</surname><given-names>CJ</given-names></name><name><surname>Stott</surname><given-names>DJ</given-names></name><name><surname>Westendorp</surname><given-names>RG</given-names></name><name><surname>Sheperd</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>BR</given-names></name><name><surname>Pressel</surname><given-names>SL</given-names></name><name><surname>Marchiolo</surname><given-names>R</given-names></name><name><surname>Marfisi</surname><given-names>RM</given-names></name><name><surname>Maggiono</surname><given-names>AP</given-names></name><name><surname>Tavazzi</surname><given-names>L</given-names></name><name><surname>Tognoni</surname><given-names>G</given-names></name><name><surname>Kjekshus</surname><given-names>J</given-names></name><name><surname>Pedersen</surname><given-names>TR</given-names></name><name><surname>Cook</surname><given-names>TJ</given-names></name><name><surname>Gotto</surname><given-names>AM</given-names></name><name><surname>Clearfield</surname><given-names>MB</given-names></name><name><surname>Downs</surname><given-names>JR</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Ohashi</surname><given-names>Y</given-names></name><name><surname>Mizuno</surname><given-names>K</given-names></name><name><surname>Ray</surname><given-names>KK</given-names></name><name><surname>Ford</surname><given-names>I</given-names></name></person-group><article-title>Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials</article-title><source>Lancet</source><year>2010</year><volume>375</volume><fpage>735</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">20167359</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>DD</given-names></name><name><surname>Ho</surname><given-names>JE</given-names></name><name><surname>DeMicco</surname><given-names>DA</given-names></name><name><surname>Breazna</surname><given-names>A</given-names></name><name><surname>Arsenault</surname><given-names>BJ</given-names></name><name><surname>Wun</surname><given-names>CC</given-names></name><name><surname>Kastelein</surname><given-names>JJ</given-names></name><name><surname>Colhoun</surname><given-names>H</given-names></name><name><surname>Barter</surname><given-names>P</given-names></name></person-group><article-title>Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials.</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>57</volume><fpage>1535</fpage><lpage>1545</lpage><pub-id pub-id-type="pmid">21453832</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlinson</surname><given-names>SS</given-names></name><name><surname>Mangione</surname><given-names>KK</given-names></name></person-group><article-title>Potential adverse effects of statins on muscle</article-title><source>Phys Ther</source><year>2005</year><volume>85</volume><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">15842193</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preiss</surname><given-names>D</given-names></name><name><surname>Seshasai</surname><given-names>SR</given-names></name><name><surname>Welsh</surname><given-names>P</given-names></name><name><surname>Murphy</surname><given-names>SA</given-names></name><name><surname>Ho</surname><given-names>JE</given-names></name><name><surname>Waters</surname><given-names>DD</given-names></name><name><surname>DeMicco</surname><given-names>DA</given-names></name><name><surname>Barter</surname><given-names>P</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Sabatine</surname><given-names>MS</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Kastelein</surname><given-names>JJ</given-names></name><name><surname>de Lemos</surname><given-names>JA</given-names></name><name><surname>Blaznig</surname><given-names>MA</given-names></name><name><surname>Pedersen</surname><given-names>TR</given-names></name><name><surname>Tikkanen</surname><given-names>MJ</given-names></name><name><surname>Sattar</surname><given-names>N</given-names></name><name><surname>Ray</surname><given-names>KK</given-names></name></person-group><article-title>Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis</article-title><source>JAMA</source><year>2011</year><volume>305</volume><fpage>2556</fpage><lpage>2564</lpage><pub-id pub-id-type="pmid">21693744</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallinson</surname><given-names>JE</given-names></name><name><surname>Sidaway</surname><given-names>J</given-names></name><name><surname>Westwood</surname><given-names>FR</given-names></name><name><surname>Greenhaff</surname><given-names>PL</given-names></name></person-group><article-title>Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy</article-title><source>J Physiol</source><year>2009</year><volume>587</volume><fpage>219</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">19001041</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>D</given-names></name><name><surname>Blizzard</surname><given-names>L</given-names></name><name><surname>Fell</surname><given-names>L</given-names></name><name><surname>Jones</surname><given-names>G</given-names></name></person-group><article-title>Statin therapy, muscle function and falls risk in community-dwelling older adults</article-title><source>QJM</source><year>2009</year><volume>102</volume><fpage>625</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">19633029</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gambelli</surname><given-names>S</given-names></name><name><surname>Dotti</surname><given-names>MT</given-names></name><name><surname>Malandrini</surname><given-names>A</given-names></name><name><surname>Mondelli</surname><given-names>M</given-names></name><name><surname>Stromillo</surname><given-names>ML</given-names></name><name><surname>Gaudiano</surname><given-names>C</given-names></name><name><surname>Federico</surname><given-names>A</given-names></name></person-group><article-title>Mitochondrial alterations in muscle biopsies of patients on statin therapy</article-title><source>J Submiscrosc Cytol Pathol</source><year>2004</year><volume>36</volume><fpage>85</fpage><lpage>89</lpage></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirvent</surname><given-names>P</given-names></name><name><surname>Mercier</surname><given-names>J</given-names></name><name><surname>Lacampagne</surname><given-names>A</given-names></name></person-group><article-title>New insights into mechanisms of statin-associated myotoxocity</article-title><source>Curr Opin Pharmacol</source><year>2008</year><volume>8</volume><fpage>333</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">18243052</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draeger</surname><given-names>A</given-names></name><name><surname>Sanchez-Freire</surname><given-names>V</given-names></name><name><surname>Monastyrskaya</surname><given-names>K</given-names></name><name><surname>Hoppeler</surname><given-names>H</given-names></name><name><surname>Mueller</surname><given-names>M</given-names></name><name><surname>Breil</surname><given-names>F</given-names></name><name><surname>Mohaupt</surname><given-names>MG</given-names></name><name><surname>Babiychuk</surname><given-names>EB</given-names></name></person-group><article-title>Statin therapy and the expression of genes that regulate calcium homeostasis and membrane repair in skeletal muscle</article-title><source>Am J Pathol</source><year>2010</year><volume>177</volume><fpage>291</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">20489141</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyle</surname><given-names>UG</given-names></name><name><surname>Bosaeus</surname><given-names>I</given-names></name><name><surname>DeLorenzo</surname><given-names>AD</given-names></name><name><surname>Deurenberg</surname><given-names>P</given-names></name><name><surname>Elia</surname><given-names>M</given-names></name><name><surname>Gomez</surname><given-names>JM</given-names></name><name><surname>Heitman</surname><given-names>BL</given-names></name><name><surname>Kent-Smith</surname><given-names>L</given-names></name><name><surname>Melchoir</surname><given-names>JC</given-names></name><name><surname>Pirlich</surname><given-names>M</given-names></name><name><surname>Scharfetter</surname><given-names>H</given-names></name><name><surname>Schols</surname><given-names>AM</given-names></name><name><surname>Pichard</surname><given-names>C</given-names></name><collab>Composition of the ESPEN Working group</collab></person-group><article-title>Bioelectrical impedance analysis &#x02013; part I: review of principles and methods</article-title><source>Clin Nutr</source><year>2004</year><volume>23</volume><fpage>1226</fpage><lpage>1243</lpage><pub-id pub-id-type="pmid">15380917</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosy-Westphal</surname><given-names>A</given-names></name><name><surname>Later</surname><given-names>W</given-names></name><name><surname>Hitze</surname><given-names>B</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Kossel</surname><given-names>E</given-names></name><name><surname>Gl&#x000fc;er</surname><given-names>CC</given-names></name><name><surname>Heller</surname><given-names>M</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>MJ</given-names></name></person-group><article-title>Accuracy of bioelectrical impedance consumer devices for measurement of body composition in comparison to whole body magnetic resonance imaging in dual-X ray absorptiometry</article-title><source>Obes Facts</source><year>2008</year><volume>1</volume><fpage>319</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">20054195</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamboni</surname><given-names>M</given-names></name><name><surname>Zoico</surname><given-names>E</given-names></name><name><surname>Scartezzini</surname><given-names>T</given-names></name><name><surname>Mazzali</surname><given-names>G</given-names></name><name><surname>Tosoni</surname><given-names>P</given-names></name><name><surname>Zivelonghi</surname><given-names>A</given-names></name><name><surname>Gallagher</surname><given-names>D</given-names></name><name><surname>DePergola</surname><given-names>G</given-names></name><name><surname>Di Francesco</surname><given-names>V</given-names></name><name><surname>Bosello</surname><given-names>O</given-names></name></person-group><article-title>Body composition changes in stable-weight elderly subjects: the effect of sex</article-title><source>Aging Clin Exp Res</source><year>2003</year><volume>15</volume><fpage>321</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">14661824</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeulen</surname><given-names>A</given-names></name><name><surname>Goemaere</surname><given-names>S</given-names></name><name><surname>Kaufman</surname><given-names>JM</given-names></name></person-group><article-title>Testosterone, body composition and aging</article-title><source>J Endocrinol Invest</source><year>1999</year><volume>22</volume><fpage>S110</fpage><lpage>S116</lpage></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manini</surname><given-names>TM</given-names></name><name><surname>Everhart</surname><given-names>JE</given-names></name><name><surname>Anton</surname><given-names>SD</given-names></name><name><surname>Schoeller</surname><given-names>DA</given-names></name><name><surname>Cummings</surname><given-names>SR</given-names></name><name><surname>Mackey</surname><given-names>DC</given-names></name><name><surname>Delmonico</surname><given-names>MJ</given-names></name><name><surname>Bauer</surname><given-names>DC</given-names></name><name><surname>Simonsick</surname><given-names>EM</given-names></name><name><surname>Colbert</surname><given-names>LH</given-names></name><name><surname>Visser</surname><given-names>M</given-names></name><name><surname>Tylavsky</surname><given-names>F</given-names></name><name><surname>Newman</surname><given-names>AB</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name></person-group><article-title>Activity energy expenditure and change in body composition in late life</article-title><source>Am J Clin Nutr</source><year>2009</year><volume>90</volume><fpage>1336</fpage><lpage>1342</lpage><pub-id pub-id-type="pmid">19740971</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riechman</surname><given-names>SE</given-names></name><name><surname>Andrews</surname><given-names>RD</given-names></name><name><surname>Maclean</surname><given-names>DA</given-names></name><name><surname>Sheater</surname><given-names>S</given-names></name></person-group><article-title>Statins and dietary and serum cholesterol are associated with increased lean mass following resistance training</article-title><source>J Gerontol A Biol Sci Acad Sci</source><year>2007</year><volume>62</volume><fpage>1164</fpage><lpage>1171</lpage></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>JE</given-names></name><name><surname>Henderson</surname><given-names>NR</given-names></name><name><surname>Ramage</surname><given-names>L</given-names></name><name><surname>McMurdo</surname><given-names>ME</given-names></name><name><surname>Witham</surname><given-names>MD</given-names></name></person-group><article-title>Association between statin medication use and improved outcomes during inpatients rehabilitation in older people</article-title><source>Age Ageing</source><year>2012</year><volume>41</volume><fpage>260</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">22156557</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonati</surname><given-names>JG</given-names></name><name><surname>Modeneze</surname><given-names>DM</given-names></name><name><surname>Vilarth</surname><given-names>R</given-names></name><name><surname>Maciel</surname><given-names>ES</given-names></name><name><surname>Boccacetto</surname><given-names>ER</given-names></name></person-group><article-title>Body weight as an indicator of fat-free mass in active elderly women</article-title><source>Maturitas</source><year>2011</year><volume>68</volume><fpage>378</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">21295423</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stucke</surname><given-names>G</given-names></name><name><surname>Br&#x000fc;hlmann</surname><given-names>P</given-names></name><name><surname>Stoll</surname><given-names>T</given-names></name><name><surname>Stucke</surname><given-names>S</given-names></name><name><surname>Willer</surname><given-names>P</given-names></name><name><surname>Michael</surname><given-names>BA</given-names></name></person-group><article-title>Low serum creatine kinase activity is associated with muscle weakness in patients with rheumatoid arthritis</article-title><source>J Rheumatol</source><year>1996</year><volume>23</volume><fpage>603</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">8730112</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Connell</surname><given-names>K</given-names></name><name><surname>Gannon</surname><given-names>J</given-names></name><name><surname>Doran</surname><given-names>P</given-names></name><name><surname>Ohlendieck</surname><given-names>K</given-names></name></person-group><article-title>Proteomic profiling reveals a severely perturbed protein expression pattern in aged skeletal muscle</article-title><source>Int J Mol Med</source><year>2007</year><volume>20</volume><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">17611631</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>AS</given-names></name><name><surname>Janssen</surname><given-names>I</given-names></name><name><surname>Sui</surname><given-names>X</given-names></name><name><surname>Church</surname><given-names>TS</given-names></name><name><surname>Blair</surname><given-names>SN</given-names></name></person-group><article-title>Longitudinal changes in body composition associated with healthy aging men aged 20&#x02013;96 years</article-title><source>Br J Nutr</source><year>2011</year><volume>3</volume><fpage>1</fpage><lpage>7</lpage></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dzien</surname><given-names>A</given-names></name><name><surname>Winner</surname><given-names>H</given-names></name><name><surname>Theurl</surname><given-names>E</given-names></name><name><surname>Dzien-Bischinger</surname><given-names>C</given-names></name><name><surname>Lechleitner</surname><given-names>M</given-names></name></person-group><article-title>Body mass index in a large cohort of patients assigned to age decades between &#x0003c;20 and &#x0003e;80 years: relationship with cardiovascular morbidity and medication</article-title><source>J Nutr Health Aging</source><year>2011</year><volume>15</volume><fpage>536</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">21808931</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brinkley</surname><given-names>TE</given-names></name><name><surname>Hsu</surname><given-names>FC</given-names></name><name><surname>Beavers</surname><given-names>KM</given-names></name><name><surname>Church</surname><given-names>TS</given-names></name><name><surname>Goodpaster</surname><given-names>BH</given-names></name><name><surname>Stafford</surname><given-names>RS</given-names></name><name><surname>Pahor</surname><given-names>M</given-names></name><name><surname>Kritchevsky</surname><given-names>SB</given-names></name><name><surname>Nicklas</surname><given-names>BJ</given-names></name></person-group><article-title>Total and abdominal adiposity are associated with inflammation in older adults using a factor analysis approach</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2012</year><volume>67</volume><fpage>1099</fpage><lpage>1106</lpage><pub-id pub-id-type="pmid">22451470</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cesari</surname><given-names>M</given-names></name><name><surname>Kritchevsky</surname><given-names>SB</given-names></name><name><surname>Baumgartner</surname><given-names>RN</given-names></name><name><surname>Atkinson</surname><given-names>HH</given-names></name><name><surname>Penninx</surname><given-names>BW</given-names></name><name><surname>Lenchik</surname><given-names>L</given-names></name><name><surname>Palla</surname><given-names>SL</given-names></name><name><surname>Ambrosius</surname><given-names>WT</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>Pahor</surname><given-names>M</given-names></name></person-group><article-title>Sarcopenia, obesity, and inflammation &#x02013; results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factor study</article-title><source>Am J Clin Nutr</source><year>2005</year><volume>82</volume><fpage>428</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">16087989</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bu</surname><given-names>DX</given-names></name><name><surname>Griffin</surname><given-names>G</given-names></name><name><surname>Lichtman</surname><given-names>AH</given-names></name></person-group><article-title>Mechanisms for the anti-inflammatory effects of statins</article-title><source>Curr Opin Lipidol</source><year>2011</year><volume>22</volume><fpage>165</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">21412153</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandler-Laney</surname><given-names>PC</given-names></name><name><surname>Phadke</surname><given-names>RP</given-names></name><name><surname>Granger</surname><given-names>WM</given-names></name><name><surname>Fernandez</surname><given-names>JR</given-names></name><name><surname>Nunoz</surname><given-names>JA</given-names></name><name><surname>Man</surname><given-names>CD</given-names></name><name><surname>Cobelli</surname><given-names>C</given-names></name><name><surname>Ovalle</surname><given-names>F</given-names></name><name><surname>Gower</surname><given-names>BA</given-names></name></person-group><article-title>Age-related changes in insulin sensitivity and beta-cell function among European-American and African-American women</article-title><source>Obesity</source><year>2011</year><volume>19</volume><fpage>528</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">20885386</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominguez</surname><given-names>LJ</given-names></name><name><surname>Barbagallo</surname><given-names>M</given-names></name></person-group><article-title>The cardiometabolic syndrome and sarcopenic obesity in older persons</article-title><source>J Cardiomet Syndr</source><year>2007</year><volume>2</volume><fpage>183</fpage><lpage>189</lpage></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolovou</surname><given-names>G</given-names></name><name><surname>Bilianou</surname><given-names>H</given-names></name><name><surname>Marvaki</surname><given-names>A</given-names></name><name><surname>Mikhailidis</surname><given-names>DP</given-names></name></person-group><article-title>Aging men and lipids</article-title><source>Am J Mens Health</source><year>2011</year><volume>5</volume><fpage>152</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">20483870</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spinar</surname><given-names>J</given-names></name><name><surname>Ludka</surname><given-names>O</given-names></name><name><surname>Senkyrikova</surname><given-names>M</given-names></name><name><surname>Vitovec</surname><given-names>J</given-names></name><name><surname>Spinarova</surname><given-names>L</given-names></name><name><surname>Dusek</surname><given-names>L</given-names></name></person-group><article-title>Cholesterol levels according to age</article-title><source>Vnitr Lek</source><year>2009</year><volume>55</volume><fpage>724</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">19785369</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name></person-group><article-title>Statins and safety: can we finally be reassured?</article-title><source>Lancet</source><year>2011</year><volume>378</volume><fpage>1980</fpage><lpage>1981</lpage><pub-id pub-id-type="pmid">22115875</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Sample characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th align="left" rowspan="1" colspan="1">Age cohort</th><th align="left" rowspan="1" colspan="1">Observed</th><th align="left" rowspan="1" colspan="1">BMI</th><th align="left" rowspan="1" colspan="1">BFM</th><th align="left" rowspan="1" colspan="1">FFM</th><th align="left" rowspan="1" colspan="1">CPK</th><th align="left" rowspan="1" colspan="1">FGL</th><th align="left" rowspan="1" colspan="1">Total c</th><th align="left" rowspan="1" colspan="1">TG</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Non-statin users</italic></bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;60</td><td align="left" rowspan="1" colspan="1">1,978</td><td align="left" rowspan="1" colspan="1">24.08</td><td align="left" rowspan="1" colspan="1">23.80</td><td align="left" rowspan="1" colspan="1">52.99</td><td align="left" rowspan="1" colspan="1">119.34</td><td align="left" rowspan="1" colspan="1">93.71</td><td align="left" rowspan="1" colspan="1">203.94</td><td align="left" rowspan="1" colspan="1">114.46</td></tr><tr><td align="left" rowspan="1" colspan="1">60&#x02013;75</td><td align="left" rowspan="1" colspan="1">404</td><td align="left" rowspan="1" colspan="1">26.10</td><td align="left" rowspan="1" colspan="1">32.40</td><td align="left" rowspan="1" colspan="1">50.87</td><td align="left" rowspan="1" colspan="1">122.73</td><td align="left" rowspan="1" colspan="1">108.38</td><td align="left" rowspan="1" colspan="1">227.73</td><td align="left" rowspan="1" colspan="1">131.29</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;75</td><td align="left" rowspan="1" colspan="1">298</td><td align="left" rowspan="1" colspan="1">24.58</td><td align="left" rowspan="1" colspan="1">34.54</td><td align="left" rowspan="1" colspan="1">44.52</td><td align="left" rowspan="1" colspan="1">111.57</td><td align="left" rowspan="1" colspan="1">113.00</td><td align="left" rowspan="1" colspan="1">219.82</td><td align="left" rowspan="1" colspan="1">130.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">2,680</td><td align="left" rowspan="1" colspan="1">24.44</td><td align="left" rowspan="1" colspan="1">26.29</td><td align="left" rowspan="1" colspan="1">51.73</td><td align="left" rowspan="1" colspan="1">118.99</td><td align="left" rowspan="1" colspan="1">98.10</td><td align="left" rowspan="1" colspan="1">209.34</td><td align="left" rowspan="1" colspan="1">118.80</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Statin users</italic></bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;60</td><td align="left" rowspan="1" colspan="1">152</td><td align="left" rowspan="1" colspan="1">27.46</td><td align="left" rowspan="1" colspan="1">29.28</td><td align="left" rowspan="1" colspan="1">58.37</td><td align="left" rowspan="1" colspan="1">133.18</td><td align="left" rowspan="1" colspan="1">113.20</td><td align="left" rowspan="1" colspan="1">226.46</td><td align="left" rowspan="1" colspan="1">176.99</td></tr><tr><td align="left" rowspan="1" colspan="1">60&#x02013;75</td><td align="left" rowspan="1" colspan="1">293</td><td align="left" rowspan="1" colspan="1">26.68</td><td align="left" rowspan="1" colspan="1">32.53</td><td align="left" rowspan="1" colspan="1">51.85</td><td align="left" rowspan="1" colspan="1">135.78</td><td align="left" rowspan="1" colspan="1">113.93</td><td align="left" rowspan="1" colspan="1">210.17</td><td align="left" rowspan="1" colspan="1">151.18</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;75</td><td align="left" rowspan="1" colspan="1">155</td><td align="left" rowspan="1" colspan="1">25.84</td><td align="left" rowspan="1" colspan="1">34.68</td><td align="left" rowspan="1" colspan="1">47.49</td><td align="left" rowspan="1" colspan="1">118.43</td><td align="left" rowspan="1" colspan="1">116.48</td><td align="left" rowspan="1" colspan="1">212.76</td><td align="left" rowspan="1" colspan="1">138.69</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">600</td><td align="left" rowspan="1" colspan="1">26.66</td><td align="left" rowspan="1" colspan="1">32.26</td><td align="left" rowspan="1" colspan="1">52.38</td><td align="left" rowspan="1" colspan="1">130.64</td><td align="left" rowspan="1" colspan="1">114.40</td><td align="left" rowspan="1" colspan="1">214.98</td><td align="left" rowspan="1" colspan="1">154.50</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Statin users with CPK&#x0003e; 170</italic></bold></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;60</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">28.35</td><td align="left" rowspan="1" colspan="1">29.10</td><td align="left" rowspan="1" colspan="1">60.99</td><td align="left" rowspan="1" colspan="1">232.24</td><td align="left" rowspan="1" colspan="1">117.96</td><td align="left" rowspan="1" colspan="1">227.02</td><td align="left" rowspan="1" colspan="1">177.98</td></tr><tr><td align="left" rowspan="1" colspan="1">60&#x02013;75</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">27.07</td><td align="left" rowspan="1" colspan="1">32.14</td><td align="left" rowspan="1" colspan="1">53.60</td><td align="left" rowspan="1" colspan="1">260.70</td><td align="left" rowspan="1" colspan="1">111.93</td><td align="left" rowspan="1" colspan="1">199.20</td><td align="left" rowspan="1" colspan="1">164.93</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;75</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">26.16</td><td align="left" rowspan="1" colspan="1">33.38</td><td align="left" rowspan="1" colspan="1">50.36</td><td align="left" rowspan="1" colspan="1">268.70</td><td align="left" rowspan="1" colspan="1">128.20</td><td align="left" rowspan="1" colspan="1">207.43</td><td align="left" rowspan="1" colspan="1">145.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">27.29</td><td align="left" rowspan="1" colspan="1">31.45</td><td align="left" rowspan="1" colspan="1">55.23</td><td align="left" rowspan="1" colspan="1">253.63</td><td align="left" rowspan="1" colspan="1">116.59</td><td align="left" rowspan="1" colspan="1">208.93</td><td align="left" rowspan="1" colspan="1">165.32</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">BMI cohort</th><th align="left" rowspan="1" colspan="1">Observed</th><th align="left" rowspan="1" colspan="1">Age</th><th align="left" rowspan="1" colspan="1">BFM</th><th align="left" rowspan="1" colspan="1">FFM</th><th align="left" rowspan="1" colspan="1">CPK</th><th align="left" rowspan="1" colspan="1">FGL</th><th align="left" rowspan="1" colspan="1">Total c</th><th align="left" rowspan="1" colspan="1">TG</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Non-statin users</italic></bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;25</td><td align="left" rowspan="1" colspan="1">1,656</td><td align="left" rowspan="1" colspan="1">43.70</td><td align="left" rowspan="1" colspan="1">22.83</td><td align="left" rowspan="1" colspan="1">48.02</td><td align="left" rowspan="1" colspan="1">109.81</td><td align="left" rowspan="1" colspan="1">93.94</td><td align="left" rowspan="1" colspan="1">205.35</td><td align="left" rowspan="1" colspan="1">103.96</td></tr><tr><td align="left" rowspan="1" colspan="1">25&#x02013;30</td><td align="left" rowspan="1" colspan="1">706</td><td align="left" rowspan="1" colspan="1">52.86</td><td align="left" rowspan="1" colspan="1">29.69</td><td align="left" rowspan="1" colspan="1">56.19</td><td align="left" rowspan="1" colspan="1">136.61</td><td align="left" rowspan="1" colspan="1">102.21</td><td align="left" rowspan="1" colspan="1">216.53</td><td align="left" rowspan="1" colspan="1">138.88</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;30</td><td align="left" rowspan="1" colspan="1">317</td><td align="left" rowspan="1" colspan="1">52.60</td><td align="left" rowspan="1" colspan="1">36.80</td><td align="left" rowspan="1" colspan="1">61.10</td><td align="left" rowspan="1" colspan="1">127.78</td><td align="left" rowspan="1" colspan="1">110.43</td><td align="left" rowspan="1" colspan="1">214.01</td><td align="left" rowspan="1" colspan="1">150.86</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">2,679</td><td align="left" rowspan="1" colspan="1">47.17</td><td align="left" rowspan="1" colspan="1">26.29</td><td align="left" rowspan="1" colspan="1">51.72</td><td align="left" rowspan="1" colspan="1">119.00</td><td align="left" rowspan="1" colspan="1">98.10</td><td align="left" rowspan="1" colspan="1">209.34</td><td align="left" rowspan="1" colspan="1">118.80</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Statin users</italic></bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;25</td><td align="left" rowspan="1" colspan="1">225</td><td align="left" rowspan="1" colspan="1">68.67</td><td align="left" rowspan="1" colspan="1">29.07</td><td align="left" rowspan="1" colspan="1">46.45</td><td align="left" rowspan="1" colspan="1">125.25</td><td align="left" rowspan="1" colspan="1">107.63</td><td align="left" rowspan="1" colspan="1">218.96</td><td align="left" rowspan="1" colspan="1">140.62</td></tr><tr><td align="left" rowspan="1" colspan="1">25&#x02013;30</td><td align="left" rowspan="1" colspan="1">253</td><td align="left" rowspan="1" colspan="1">66.76</td><td align="left" rowspan="1" colspan="1">32.33</td><td align="left" rowspan="1" colspan="1">54.37</td><td align="left" rowspan="1" colspan="1">130.59</td><td align="left" rowspan="1" colspan="1">112.53</td><td align="left" rowspan="1" colspan="1">213.37</td><td align="left" rowspan="1" colspan="1">153.93</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;30</td><td align="left" rowspan="1" colspan="1">122</td><td align="left" rowspan="1" colspan="1">65.53</td><td align="left" rowspan="1" colspan="1">37.99</td><td align="left" rowspan="1" colspan="1">59.18</td><td align="left" rowspan="1" colspan="1">140.70</td><td align="left" rowspan="1" colspan="1">130.60</td><td align="left" rowspan="1" colspan="1">211.06</td><td align="left" rowspan="1" colspan="1">181.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">600</td><td align="left" rowspan="1" colspan="1">67.23</td><td align="left" rowspan="1" colspan="1">32.26</td><td align="left" rowspan="1" colspan="1">52.38</td><td align="left" rowspan="1" colspan="1">130.64</td><td align="left" rowspan="1" colspan="1">114.40</td><td align="left" rowspan="1" colspan="1">214.98</td><td align="left" rowspan="1" colspan="1">154.50</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Statin users with CPK &#x0003e; 170</italic></bold></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;25</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">67.84</td><td align="left" rowspan="1" colspan="1">28.41</td><td align="left" rowspan="1" colspan="1">48.82</td><td align="left" rowspan="1" colspan="1">260.22</td><td align="left" rowspan="1" colspan="1">107.34</td><td align="left" rowspan="1" colspan="1">217.79</td><td align="left" rowspan="1" colspan="1">171.87</td></tr><tr><td align="left" rowspan="1" colspan="1">25&#x02013;30</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">65.02</td><td align="left" rowspan="1" colspan="1">31.02</td><td align="left" rowspan="1" colspan="1">55.97</td><td align="left" rowspan="1" colspan="1">254.90</td><td align="left" rowspan="1" colspan="1">114.50</td><td align="left" rowspan="1" colspan="1">207.03</td><td align="left" rowspan="1" colspan="1">156.15</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;30</td><td align="left" rowspan="1" colspan="1">32</td><td align="left" rowspan="1" colspan="1">64.07</td><td align="left" rowspan="1" colspan="1">36.38</td><td align="left" rowspan="1" colspan="1">62.77</td><td align="left" rowspan="1" colspan="1">242.39</td><td align="left" rowspan="1" colspan="1">132.88</td><td align="left" rowspan="1" colspan="1">200.00</td><td align="left" rowspan="1" colspan="1">172.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">65.73</td><td align="left" rowspan="1" colspan="1">31.45</td><td align="left" rowspan="1" colspan="1">55.23</td><td align="left" rowspan="1" colspan="1">253.63</td><td align="left" rowspan="1" colspan="1">116.59</td><td align="left" rowspan="1" colspan="1">208.93</td><td align="left" rowspan="1" colspan="1">165.32</td></tr></tbody></table><table-wrap-foot><fn><p>BFM = body fat mass in %; FFM = fat-free mass in %; CPK = creatine phosphokinase (U/l); FGL = fasting glucose (mg/dl); total c = total cholesterol (mg/dl); TG = triglycerides (mg/dl).</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Impact of statin therapy on fat-free mass<xref ref-type="table-fn" rid="T2F1"><sup>a</sup></xref></p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">All patients</th><th align="left" rowspan="1" colspan="1">Patients with CPK &#x02264; 170</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex (1 = male)</td><td align="left" rowspan="1" colspan="1">16.9298 (0.2465)<xref ref-type="table-fn" rid="T2F2">***</xref></td><td align="left" rowspan="1" colspan="1">16.4383 (0.2799)<xref ref-type="table-fn" rid="T2F2">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">&#x02212;0.1274 (0.0069)<xref ref-type="table-fn" rid="T2F2">***</xref></td><td align="left" rowspan="1" colspan="1">&#x02212;0.1281 (0.0075)<xref ref-type="table-fn" rid="T2F2">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Nicotine consumption (0 = no; 1 = yes)</td><td align="left" rowspan="1" colspan="1">0.1427 (0.2742)</td><td align="left" rowspan="1" colspan="1">0.0274 (0.2915)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sports activity (0 = no; 1 = yes)</td><td align="left" rowspan="1" colspan="1">0.1164 (0.2285)</td><td align="left" rowspan="1" colspan="1">0.3669 (0.2495)</td></tr><tr><td align="left" rowspan="1" colspan="1">Statin use</td><td align="left" rowspan="1" colspan="1">7.4048 (1.8506)<xref ref-type="table-fn" rid="T2F2">***</xref></td><td align="left" rowspan="1" colspan="1">7.0191 (2.0611)<xref ref-type="table-fn" rid="T2F2">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Statin use &#x000d7; age</td><td align="left" rowspan="1" colspan="1">&#x02212;0.0947 (0.0274)<xref ref-type="table-fn" rid="T2F2">***</xref></td><td align="left" rowspan="1" colspan="1">&#x02212;0.0859 (0.0305)<xref ref-type="table-fn" rid="T2F2">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Observations</td><td align="left" rowspan="1" colspan="1">3.214</td><td align="left" rowspan="1" colspan="1">2.613</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>R</italic>
<sup>2</sup></td><td align="left" rowspan="1" colspan="1">0.64</td><td align="left" rowspan="1" colspan="1">0.62</td></tr></tbody></table><table-wrap-foot><fn id="T2F1"><label>a</label><p>Constant suppressed. Standard errors in parentheses.</p></fn><fn id="T2F2"><label>***</label><p>Indicates significance at the 1% level.</p></fn></table-wrap-foot></table-wrap></floats-group></article>